Tags

Type your tag names separated by a space and hit enter

[Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
Dtsch Med Wochenschr. 2005 Mar 24; 130(12):665-8.DM

Abstract

Blocking the endocannabinoid system is an option that substantially reduces cardiovascular risk beyond reducing body weight. Endocannabinoids and their receptors are expressed in the central nervous system as well as in the peripheral organs and regulate the central circuits for food uptake and peripheral metabolic circuits. Within the context of food uptake the cannabinoid receptors 1 (CB (1)-receptor) is of crucial importance. Its stimulation with Delta (9)-tetrahydrocannabiol (Delta (9)-THC) or its blockade with rimonabant are clinically relevant therapeutic means to maintain body weight. Rimonabant is the first of a new class of drugs, that interferes with the endocannabinoid system by blocking the CB (1)-Receptor. In recent clinical studies a substantial reduction of body weight and waist circumference was associated with an improvement of the cardiovascular risk profile, which was marked by increased HDL-cholesterol, serum triglycerides and improved insulin sensivity.

Authors+Show Affiliations

Institut für Klinische Pharmakologie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden. peter.bramlage@mailbox.tu-dresden.deNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

ger

PubMed ID

15776349

Citation

Bramlage, P, et al. "[Blocking the Endocannabinoid System -- Weight Reduction and Cardiovascular Risk Management]." Deutsche Medizinische Wochenschrift (1946), vol. 130, no. 12, 2005, pp. 665-8.
Bramlage P, Böcking W, Kirch W. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. Dtsch Med Wochenschr. 2005;130(12):665-8.
Bramlage, P., Böcking, W., & Kirch, W. (2005). [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. Deutsche Medizinische Wochenschrift (1946), 130(12), 665-8.
Bramlage P, Böcking W, Kirch W. [Blocking the Endocannabinoid System -- Weight Reduction and Cardiovascular Risk Management]. Dtsch Med Wochenschr. 2005 Mar 24;130(12):665-8. PubMed PMID: 15776349.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. AU - Bramlage,P, AU - Böcking,W, AU - Kirch,W, PY - 2005/3/19/pubmed PY - 2005/4/30/medline PY - 2005/3/19/entrez SP - 665 EP - 8 JF - Deutsche medizinische Wochenschrift (1946) JO - Dtsch Med Wochenschr VL - 130 IS - 12 N2 - Blocking the endocannabinoid system is an option that substantially reduces cardiovascular risk beyond reducing body weight. Endocannabinoids and their receptors are expressed in the central nervous system as well as in the peripheral organs and regulate the central circuits for food uptake and peripheral metabolic circuits. Within the context of food uptake the cannabinoid receptors 1 (CB (1)-receptor) is of crucial importance. Its stimulation with Delta (9)-tetrahydrocannabiol (Delta (9)-THC) or its blockade with rimonabant are clinically relevant therapeutic means to maintain body weight. Rimonabant is the first of a new class of drugs, that interferes with the endocannabinoid system by blocking the CB (1)-Receptor. In recent clinical studies a substantial reduction of body weight and waist circumference was associated with an improvement of the cardiovascular risk profile, which was marked by increased HDL-cholesterol, serum triglycerides and improved insulin sensivity. SN - 0012-0472 UR - https://www.unboundmedicine.com/medline/citation/15776349/[Blocking_the_endocannabinoid_system____weight_reduction_and_cardiovascular_risk_management]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-865077 DB - PRIME DP - Unbound Medicine ER -